Live attenuated influenza vaccine (LAIV): Recent effectiveness results from the USA and implications for LAIV programmes elsewhere

Archives of Disease in Childhood

Volumn 103, Issue 1, 2018, Pages 101-105

  Pebody, Richard ^a   McMenamin, Jim ^b   Nohynek, Hanna ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b HEALTH PROTECTION SCOTLAND   (United Kingdom)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

DRUG EFFICACY; DRUG USE; FINLAND; HEALTH PROGRAM; HUMAN; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A(H1N1)PDM09; INFLUENZA B; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION; CHILD; INFANT;

CHILD; FINLAND; HUMANS; INFANT; INFLUENZA VACCINES; INFLUENZA, HUMAN; UNITED KINGDOM; UNITED STATES; VACCINES, ATTENUATED;

EID: 85039045401     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2016-312165     Document Type: Review

References (36)

1. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and Control of Seasonal Influenza with vaccines. MMWR Recomm Rep 2016;65:1–54.
2. Pebody R, Warburton F, Ellis J, et al. Effectiveness of seasonal influenza vaccine for adults and children in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2015/16 end-of-season results. Euro Surveill 2016;21.
3. Nohynek H, Baum U, Syrjänen R, et al. Effectiveness of the live attenuated and the inactivated influenza vaccine in two-year-olds - a nationwide cohort study Finland, influenza season 2015/16. Euro Surveill 2016;21.
4. WHO Headquarters. WHO meeting on live attenuated influenza vaccine effectiveness 20-21. Geneva, Switzerland: WHO Headquarters, 2016. http://www.who.int/immunization/research/meetings_workshops/live_attenuated_influenza_vaccine_ effectiveness_sept_2016/en
5. Penttinen PM, Friede MH. Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge? Euro Surveill 2016;21.
6. Caspard H, Mallory RM, Yu J, et al. Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015–2016: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 2017;4.
7. Alexandrova GI, Budilovsky GN, Koval TA, et al. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine 1986;4:114–8.
8. Using Live, Attenuated Influenza Vaccine for Prevention and Control of Influenza: Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5213a1.htm% 5C
9. Gaglani M, Pruszynski J, Murthy K, et al. Influenza vaccine effectiveness against 2009 pandemic influenza A(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis 2016;213:1546–56.
10. Chung JR, Flannery B, Thompson MG, et al. Seasonal Effectiveness of Live attenuated and inactivated Influenza Vaccine. Pediatrics 2016;137:e20153279.
11. Griffin MR, Monto AS, Belongia EA, et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One 2011;6:e23085.
12. Cotter CR, Jin H, Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog 2014;10:e1003831.
13. Caspard H, Coelingh KL, Mallory RM, et al. Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States. Vaccine 2016;34:5066–72.
14. Baguelin M, Flasche S, Camacho A, et al. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med 2013;10:e1001527.
15. Hakin B, Cosford P, Harvey F. The flu immunisation programme 2013/14 – extension to children. London: Department of Health, 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/225360/Children_s_flu_letter_2013. pdf
16. Hakin B, Cosford P, Harvey F. The flu immunisation programme 2014/15 – extension to children. London: Department of Health, 2013. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/448823/FluImmunisationLetter2014_ accessible.pdf
17. Public Health England (PHE). Flu plan. Winter 2015/16. London: PHE, 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526143/Flu_Plan_Winter_2015_to_2016superseded.pdf
18. Winter. Surveillance of influenza and other respiratory viruses. UK: Winter, 2015 to 2016. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/526405/Flu_Annual_Report_2015_2016.pdf
19. Winter. Surveillance of influenza and other respiratory viruses. UK: Winter, 2013/14. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/325203/Flu_annual_report_June_2014.pdf
20. winter. Surveillance of influenza and other respiratory viruses. UK: winter, 2014 to 2015. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/429617/Annualreport_March2015_ver4.pdf
21. Pebody R, Sile B, Warburton F, et al. Live attenuated influenza vaccine effectiveness against hospitalisation due to laboratory-confirmed influenza in children two to six years of age in England in the 2015/16 season. Euro Surveill 2017;22.
22. National Services Scotland. Flu vaccine effectiveness in Scottish primary school age children from the 2015/16 season. http://www.hps.scot.nhs.uk/resourcedocument.aspx?id=5529.
23. Pebody RG, Green HK, Andrews N, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill 2014;19:20823.
24. Pebody RG, Green HK, Andrews N, et al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro surveil 2015;20.
25. Green HK, Brousseau N, Andrews N, et al. Illness absenteeism rates in primary and secondary schools in 2013-2014 in England: was there any impact of vaccinating children of primary-school age against influenza? Epidemiol Infect 2016;9:3412–21.
26. Lampos V, Yom-Tov E, Pebody R, et al. Assessing the impact of a health intervention via user-generated internet content. Data Min Knowl Discov 2015;29:1434–57.
27. Salo H, Kilpi T, Sintonen H, et al. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006;24:4934–41.
28. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012;7:e33536.
29. Helmeke C, Möhl A, Gräfe L, et al, 2016. Effectiveness of the 2015/16 tetravalent live and trivalent inactivated influenza vaccines against A(H1N1) pdm09in children and adolescents in Germany. Poster, Escaide Conference.
30. Bandell A, Woo J, Coelingh K. Protective efficacy of live-attenuated influenza vaccine (multivalent, Ann Arbor strain): a literature review addressing interference. Expert Rev Vaccines 2011;10:1131–41.
31. Klick B, Durrani S, Chan KH, et al. Live attenuated seasonal and pandemic influenza vaccine in school-age children: a randomized controlled trial. Vaccine 2013;31:1937–43.
32. Flannery B. LAIV vs IIV effectiveness: summary of evidence since 2009. Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (ACIP) Meeting, Atlanta, GA. 2016 Jun 22–23. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2016-06/influenza-07-flannery.pdf
33. Ambrose CS, Bright H, Mallory R. Letter to the editor: Potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines. Euro Surveill 2016;21.
34. WHO. Recommended composition of influenza virus vaccines for use in the 2017 southern hemisphere influenza season. 2016 http://www.who.int/influenza/vaccines/virus/recommendations/2017_south/en/.
35. European Medicines Agency. Pandemic influenza vaccine H5N1. 2017 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/ human/003963/WC500207903.pdf
36. JCVI minutes of the meeting. 2016 https://app.box.com/s/iddfb4ppwkmtjusir2tc/1/2199012147/98304591342/1